Could cause temporary or reversible harm; serious harm is unlikely.
CGMP deviation: Product found to contain trace amounts of NMBA
| Brand name | LOSARTAN POTASSIUM |
| Generic name | LOSARTAN POTASSIUM |
| Active ingredient(s) | LOSARTAN POTASSIUM |
| Distributed by / for | PD-Rx Pharmaceuticals, Inc. |
| NDC | 43063-854-60 |
| Full product label | Losartan Potassium USP, 50 mg, RX Only, Pkg By PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127 a) 60 Tablets NDC: 43063-854-60; b) 90 Tablets NDC: 43063-0854-90 |
| Recalling firm | PD-Rx Pharmaceuticals, Inc. |
| Distribution | AK, AZ, CA, CO, FL, KY, MA, MI, MN, NC, OH, OR, WI, WY |
| Quantity | 576 bottles |
| Recall initiated | 2019-03-08 |
| Report date | 2021-05-05 |
| Recall completed | 2021-06-16 |
| Recall number | D-0341-2021 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Oklahoma City OK United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗